Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers
Research led by Curve CSO Professor Ali Tavassoli’s laboratory…
STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024
Late breaking presentation on STORM’s METTL1 inhibitors, for…
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
First efficacy data from the clinical trial with HDP-101…
4SC AG provides results for financial year 2023 and outlook for 2024
Planegg-Martinsried, Germany, 22 March 2024 – 4SC AG (4SC,…
Curve Therapeutics April 2024 Conference Attendance
Southampton, UK, 21 March 2024 – Curve Therapeutics (“Curve”…
Poolbeg Pharma plc – Notice of Allowance for Significant POLB 001 Patent in United States
Notice of Allowance for Immunomodulator II further strengthens…
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
AlmeeTM is the first digital therapy to address anxiety and…
Denmark to build one of the world’s most powerful AI supercomputers, accelerating solutions to societal challenges
Denmark is entering into a collaboration with NVIDIA to establish…
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE:…
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Data from HDP-101 dose escalation shows first objective responses…
2023 Novo Holdings Bioindustrial Investments Team Annual Review/Business Update
Established the Novo Holdings Bioindustrial Investments team,…
BII welcomes innovative smartRNA project to Bio Studio program
BioInnovation Institute (BII), an international non-profit foundation,…
Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer
Financing to advance first platform designed to reprogram…
Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Deal value up to US$1.05 billion
Novo Holdings co-led Series…
Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
Co-led by RV Invest and Johnson & Johnson Innovation…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York